2013
DOI: 10.1194/jlr.m034454
|View full text |Cite
|
Sign up to set email alerts
|

Intestinal SR-BI does not impact cholesterol absorption or transintestinal cholesterol efflux in mice

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

1
30
0
1

Year Published

2013
2013
2018
2018

Publication Types

Select...
7
1
1

Relationship

0
9

Authors

Journals

citations
Cited by 33 publications
(32 citation statements)
references
References 74 publications
1
30
0
1
Order By: Relevance
“…If this finding is widely applicable, the premise that assessments of lipoproteins in afferent lymph mirror those in interstitial fluid may not hold under at least some circumstances. By contrast, the presence or absence of SR-B1 does not modulate chylomicron absorption in the intestine (53). Perhaps alternative explanations exist for the proposed role of SR-B1 in HDL transit out of the skin.…”
Section: Lipoprotein Entry Into Lymphatic Vasculature: Lessons From Cmentioning
confidence: 92%
“…If this finding is widely applicable, the premise that assessments of lipoproteins in afferent lymph mirror those in interstitial fluid may not hold under at least some circumstances. By contrast, the presence or absence of SR-B1 does not modulate chylomicron absorption in the intestine (53). Perhaps alternative explanations exist for the proposed role of SR-B1 in HDL transit out of the skin.…”
Section: Lipoprotein Entry Into Lymphatic Vasculature: Lessons From Cmentioning
confidence: 92%
“…These findings review that SR-B1 is not heavily responsible for sterol uptake and scarb1 expression might not be modulated by dietary sterols. SR-B1 was recognized as an important sterol transporter but deficiency of SR-B1 did not alter the cholesterol concentration in mammals [13,21]. These findings show that amount of imported cholesterol via SR-B1 is less compared to NPC1L1 and lipid source is required for absorption via SR-B1.…”
Section: Discussionmentioning
confidence: 64%
“…One study in SR-BI(−/−)/apoE(−/−) mice showed that ezetimibe significantly reduced aortic sinus plaque (57 %), coronary arterial occlusion (68 %), myocardial fibrosis (57 %), and cardiomegaly (12 %) compared with untreated controls [62]. Intestinal SR-BI does not impact cholesterol absorption or transintestinal cholesterol efflux in mice [63], and these favorable effects of ezetimibe on atherosclerosis may be attributed to the reduction of cholesterol in the IDL/LDL-size range. The effects of ezetimibe was also evaluated in LDL receptor(−/−)/apoE(−/−) mice [64].…”
Section: Effects Of Ezetimibe On Atherosclerosis In a Variety Of Animmentioning
confidence: 97%